| abstract |
The present invention relates to compounds having the following formula (I), It can be in the form of a base or in the form of a hydrate or solvate, which is used in combination with prednisone or prednisolone, which is used for the treatment of gastrointestinal tracts that do not have occurrences selected from the group consisting of Castration-resistant or hormone-refractory metastatic prostate cancer in patients at risk of the disease: gastrointestinal bleeding and perforation, gastritis, enterocolitis, neutropenic enterocolitis, colitis, intestinal obstruction, and intestinal colic. |